ISIS Pharmaceuticals, Inc.  

(Public, NASDAQ:ISIS)   Watch this stock  
Find more results for ISIS
63.37
+2.22 (3.63%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 61.41 - 64.44
52 week 22.25 - 77.80
Open 61.57
Vol / Avg. 4.34M/2.92M
Mkt cap 7.54B
P/E     -
Div/yield     -
EPS -0.33
Shares 119.02M
Beta 1.53
Inst. own 88%
May 4, 2015
Q1 2015 Isis Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Apr 14, 2015
Isis Pharmaceuticals Inc at Needham Healthcare Conference Add to calendar
Mar 9, 2015
Isis Pharmaceuticals Inc at ROTH Capital Annual ROTH Conference - Webcast
Mar 4, 2015
Isis Pharmaceuticals Inc at Cowen Health Care Conference
Feb 27, 2015
Q4 2014 Isis Pharmaceuticals Inc Earnings Call
Feb 27, 2015
Q4 2014 Isis Pharmaceuticals Inc Earnings Release
Feb 23, 2015
Isis Pharmaceuticals Inc at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day
Feb 11, 2015
Isis Pharmaceuticals Inc at Leerink Global Healthcare Conference
Jan 12, 2015
Isis Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 36.59% -18.20%
Operating margin 2.11% -26.16%
EBITD margin - -17.90%
Return on average assets 14.24% -4.32%
Return on average equity 41.34% -12.26%
Employees 390 -
CDP Score - -

Address

2855 Gazelle Ct
CARLSBAD, CA 92010-6670
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Isis Pharmaceuticals, Inc., is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. The Company�s primary activity is to discover and develop antisense drugs. The antisense drugs are used to treat a wide range of diseases, including severe and rare, cardiovascular, neurologic and metabolic diseases and cancer. The Company�s flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies As of December 2013 The Company has three generation 2.5 drugs in development, ISIS-STAT3Rx, ISIS-ARRx and ISIS-FVIIRx. As of December 2013 the Company has a pipeline of 31 drugs in development.

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 60
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President - Legal, General Counsel
Age: 40
Bio & Compensation  - Reuters
C. Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 58
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 57
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 53
Bio & Compensation  - Reuters
Sarah Boyce Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters